Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Featured Clinical Trials Supported by the National Cancer Institute

Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.

To find other cancer trials open to enrollment:

  • Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
  • Use the clinical trials search form to look online for trials listed on NCI's website. The form has a Help link for tips about searching for clinical trials.
  • For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
  • Using Circulating Tumor Cells to Guide Treatment
    (Posted: 10/07/2008) - In this trial, women with metastatic breast cancer who are scheduled to undergo chemotherapy will be tested to determine their blood level of circulating tumor cells (CTCs) before treatment. Those with elevated CTCs will be tested again after the first round of chemotherapy and either stay on their current chemotherapy regimen or be assigned to a new regimen if their CTCs are still elevated.
  • New Drug for Patients with Metastatic or Inoperable Kidney Cancer
    (Posted: 09/23/2008) - In this randomized trial, patients who have kidney cancer that cannot be surgically removed (unresectable) or that has spread (metastatic) and who have previously received sorafenib or sunitinib will take vandetanib daily until their disease progresses or they develop unacceptable side effects.
  • Targeting Occult Cancer Cells in High-risk Prostate Cancer Patients
    (Posted: 09/09/2008) - In this trial, prostate cancer patients classified as having a high risk of recurrence will be randomly assigned to undergo a course of neoadjuvant therapy consisting of chemotherapy and anti-androgen therapy or proceed directly to surgery.
  • Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
    (Posted: 05/13/2008, Updated: 08/11/2008) - In this clinical trial, postmenopausal women with hormone receptor-positive breast cancer that has been surgically removed will be randomly assigned to receive either anastrozole or exemestane for five years.
  • Refining Treatment for Gastrointestinal Stromal Tumors
    (Posted: 08/05/2008) - In this randomized trial, patients with unresectable or metastatic GIST will receive imatinib therapy with or without the addition of bevacizumab. Researchers hope that the combination of imatinib and bevacizumab will help extend progression-free survival.
< Previous  12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  Next >